Information Provided By:
Fly News Breaks for March 30, 2016
ACOR
Mar 30, 2016 | 06:24 EDT
Goldman Sachs analyst Salveen Richter started Acorda Therapeutics with a Sell rating and $23 price target. The analyst believes Acorda's lead product Ampyra is close to fully realizing its commercial opportunity and that intellectual property threats will present an overhang on the shares.
News For ACOR From the Last 2 Days
There are no results for your query ACOR